Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Posted on Linken
View:
Post by fasttrack5 on Nov 14, 2024 11:03pm

Posted on Linken

Behind the scenes, GCAR is working hard to finalize the Pancreatic Cancer Master Protocol trial design. 
 
Earlier this year, we shared the exciting news that we’re collaborating with Oncolytics Biotech Inc. for the evaluation of pelareorep in our forthcoming next-generation Pancreatic Cancer Master Protocol. 
 
To learn more about this groundbreaking #clinicaltrial, visit: https://lnkd.in/g3AbCB-A 
 
To learn more about our collaboration with Oncolytics Biotech Inc., visit: https://lnkd.in/eH3Cwgjc
Comment by 13X2413 on Nov 14, 2024 11:36pm
If I'm not mistaken, isn't this old news from May?
Comment by Buckhenry on Nov 15, 2024 11:54am
I'm sure glad stock price does not matter... be patient... I'm am told from a "relaible" source on here that negotiations are taking place...
Comment by 13X2413 on Nov 15, 2024 12:10pm
Matters less and less everyday. Can't wait for Notable to come up with info totally unrelated to ONC. 
Comment by fasttrack5 on Nov 15, 2024 12:23am
Just providing  a post from today on Linken. a refresher then :) RJ
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities